Browse the corpus

Famotidine is a histamine-2 (H2) receptor antagonist that reduces gastric acid secretion and is used to treat gastrointestinal conditions associated with excess acid production. The drug is available both by prescription and over the counter (OTC). Prescription indications for famotidine, as approved by the US Food and Drug Administration (FDA), include the treatment of duodenal and gastric ulcers, gastroesophageal reflux disease in adults and children, and pathological hypersecretory conditions in adults. OTC formulations are approved for the prevention and treatment of heartburn associated with GERD in both adult and pediatric populations. Off-label uses of famotidine include treatment of refractory urticaria, stress ulcer prophylaxis in critically ill patients, and symptomatic relief of gastritis. This activity outlines the indications, mechanisms of action, administration methods, significant adverse effects, contraindications, monitoring recommendations, and toxicity of famotidine. This activity also emphasizes the coordination and collaboration among interprofessional healthcare providers to individualize therapy and optimize patient outcomes. Objectives: Identify the FDA-approved and off-label indications for famotidine in adult and pediatric populations. Implement appropriate dosing regimens based on indication, age, renal function, and route of administration. Select the appropriate formulation and route of administration for famotidine based on individual patient needs. Collaborate with interprofessional healthcare providers to optimize famotidine therapy, ensuring safety, effectiveness, and reduced risk of complications. Access free multiple choice questions on this topic.

As famotidine is primarily eliminated through the kidneys, the risk of toxicity could be heightened in individuals with compromised renal function. Consequently, dosage adjustments are imperative for patients with moderate to severe renal impairment.[12][26] According to the famotidine package insert, oral doses up to 640 mg/d (exceeding FDA-approved limits) have been administered to adult patients with pathological hypersecretory conditions. Notably, this usage has not led to any severe adverse outcomes. Reported drug overdose cases resemble adverse events observed during routine clinical practice. Management of famotidine overdose involves eliminating unabsorbed drug from the gastrointestinal tract, close patient monitoring, and providing appropriate supportive care to patients. Famotidine is classified as a pregnancy category B drug and should be used during pregnancy only if the potential benefits outweigh the associated risks. The drug is detectable in breast milk; therefore, the decision to continue breastfeeding while on therapy should balance maternal benefits against potential risks to the infant. Compared with other H2RAs, famotidine appears in lower concentrations in breast milk, making it a potentially preferable option during lactation.[20][38]

In 1999, the American Society of Health-System Pharmacists (ASHP) published a guideline to prevent stress ulcers in medical, surgical, respiratory, and pediatric intensive care unit (ICU) patients. Since then, and in recent years, stress ulcer prophylaxis has been increasingly applied beyond ICU and general medical settings, despite limited evidence supporting its effectiveness. In hospital settings, up to 71% of patients on general medicine wards receive acid-suppressive therapy (AST) without a suitable indication. Furthermore, a significant number of patients continue AST even after being discharged from the hospital. This continuation can result in escalated medical expenses or higher healthcare costs and an increased risk of adverse drug reactions. The interprofessional healthcare team plays a crucial role in enhancing patient safety by minimizing the inappropriate use of AST. Physicians and advanced practice practitioners should carefully evaluate the necessity of AST for patients in the general medicine ward. Pharmacists contribute by collaborating with prescribers and inquiring about unnecessary use of AST. In contrast, nursing staff remain vigilant for potential adverse effects and promptly communicate concerns related to the therapy to the prescribing or ordering clinician. Patient education is equally important. Educating patients about the appropriate use of AST in ICU settings, as outlined in ASHP guidelines, helps reduce the use of unwarranted therapy.[39][40][41] For OTC famotidine, interprofessional care coordination is essential to ensure proper patient counseling on accurate dosing and self-monitoring for adverse effects. This collaborative approach among healthcare professionals supports optimal patient outcomes while minimizing risks and unnecessary healthcare costs.